Lamorna Brown Swigart

机构：University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of San Francisco · ORCID：0000-0003-2076-5177

发表论文 291 篇 · 总被引 8776 次 · h-index 37

代表论文

• Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors (2025 · Nature Communications · 被引 16)
• Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. (2025 · Journal of Clinical Oncology · 被引 6)
• Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial (2025 · JCO Precision Oncology · 被引 5)
• Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer (2026 · Science Translational Medicine · 被引 3)
• Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer (2025 · Clinical Cancer Research · 被引 3)
• Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial. (2025 · Journal of Clinical Oncology · 被引 3)